Product Name :
PRAK (Phospho-T182) polyclonal antibody Background :
MAPKAPK-5 belongs to the mitogen-activated protein kinase (MAPK) activated protein kinases (MK) subfamily that includes MAPKAPK-2/MK2 and MK3/3pK. The MK subfamily is part of a family of protein kinase subfamilies downstream of MAPK pathways and includes ribosomal S6 kinase (RSKs), mitogen and stress activated kinases (MSKs) and MAPK-interacting kinases (MNKs). All MKs are activated by MAPK pathways and mediate important processes (e.g. gene expression, cell cycle progression) and have been implicated in inflammation and cancer . MAPKAPK-5 shows binding to and activation by p38 MAPK and extracellular-regulated kinases (Erk) . MAPKAPK-5 was shown to be activated by Erk3 and act as a chaperone to Erk3 . While overexpressed MAPKAPK-5 shares similar substrates with MAPKAPK-2, such as HSP27 and glycogen synthase, recent work with MAPKAPK-5 knock-out mice indicates distinct substrates and functional properties . Product :
Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
Recognizes endogenous levels of PRAK with a phosphorylation site at T182 protein. Immunogen :
KLH-conjugated synthetic peptide encompassing a sequence within the center region of human PRAK with a phosphorylation site at T182. The exact sequence is proprietary. Conjugate :
Unconjugated Modification :
Phosphorylation
PRAK (Phospho-T182) polyclonal antibody Background :
MAPKAPK-5 belongs to the mitogen-activated protein kinase (MAPK) activated protein kinases (MK) subfamily that includes MAPKAPK-2/MK2 and MK3/3pK. The MK subfamily is part of a family of protein kinase subfamilies downstream of MAPK pathways and includes ribosomal S6 kinase (RSKs), mitogen and stress activated kinases (MSKs) and MAPK-interacting kinases (MNKs). All MKs are activated by MAPK pathways and mediate important processes (e.g. gene expression, cell cycle progression) and have been implicated in inflammation and cancer . MAPKAPK-5 shows binding to and activation by p38 MAPK and extracellular-regulated kinases (Erk) . MAPKAPK-5 was shown to be activated by Erk3 and act as a chaperone to Erk3 . While overexpressed MAPKAPK-5 shares similar substrates with MAPKAPK-2, such as HSP27 and glycogen synthase, recent work with MAPKAPK-5 knock-out mice indicates distinct substrates and functional properties . Product :
Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
Recognizes endogenous levels of PRAK with a phosphorylation site at T182 protein. Immunogen :
KLH-conjugated synthetic peptide encompassing a sequence within the center region of human PRAK with a phosphorylation site at T182. The exact sequence is proprietary. Conjugate :
Unconjugated Modification :
Phosphorylation
-
Western blot analysis of PRAK (pT182) expression in HCT116 (A) whole cell lysates.
-
Immunohistochemical analysis of PRAK (pT182) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
Bioworld Biotech only provide peptides for our antibodies and do not provide additional peptide customization services.
Price/Size :
USD 368/1mg/vial
Tips:
For phospho antibody, we provide phospho peptide(0.5mg) and non-phospho peptide(0.5mg).Describe :
Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (WB) and Immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or IHC performed with the neutralized antibody.Formula:
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.
Storage:
The freeze-dried powder is more stable. For short time at 2-8°C. For long term storage store at -20°C.
Note :
This product is for research use only (RUO only). Not for use in diagnostic or therapeutic procedures.